Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.amjoto.2020.102618 http://scihub22266oqcxt.onion/10.1016/j.amjoto.2020.102618 32574894!7301800!32574894     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Otolaryngol 2020 ; 41 (5): 102618 Nephropedia Template TP {{tp|p=32574894|t=2020. Repurposing 0 5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic |pdf=|usr=}}{{32574894}} gab.com Text Repurposing 0 5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic JO: Am J Otolaryngol http://www.kidney.de/pget.php?&tw=1&pmid=32574894 #FOAvip SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries. AIMS: MATERIALS AND METHODS: 0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30?s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted. RESULTS: The patient and health care workers tolerated the 0.5%. No allergy was noted. CONCLUSION: We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE. Twit Text FOAVip Repurposing 0 5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic ????Am J Otolaryngol http://www.kidney.de/pget.php?&tw=1&pmid=32574894 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32574894 #FOAvip English Wikipedia <ref>{{Cite pmid|32574894}}</ref> Repurposing 0 5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic #MMPMID32574894 Khan MM; Parab SR; Paranjape M Am J Otolaryngol 2020[Sep]; 41 (5): 102618 PMID32574894show ga SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries. AIMS: MATERIALS AND METHODS: 0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30?s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted. RESULTS: The patient and health care workers tolerated the 0.5%. No allergy was noted. CONCLUSION: We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE. |*Betacoronavirus[MESH] |*Otolaryngology[MESH] |Administration, Intranasal[MESH] |Adolescent[MESH] |Adult[MESH] |Ambulatory Care[MESH] |Anti-Infective Agents, Local/*administration & dosage[MESH] |COVID-19[MESH] |Coronavirus Infections/epidemiology/*prevention & control/transmission[MESH] |Female[MESH] |Humans[MESH] |Infectious Disease Transmission, Patient-to-Professional/prevention & control[MESH] |Infectious Disease Transmission, Professional-to-Patient/prevention & control[MESH] |Male[MESH] |Middle Aged[MESH] |Mouthwashes[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/epidemiology/*prevention & control/transmission[MESH] |Povidone-Iodine/*administration & dosage[MESH] |SARS-CoV-2[MESH]Repurposing 0 5% povidone iodine solution in otorhinolaryngology pract(epmc).pdf DeepDyve Pubget Overpricing